Matriptase protects against experimental colitis and promotes intestinal barrier recovery
Article first published online: 13 NOV 2011
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 7, pages 1303–1314, July 2012
How to Cite
Netzel-Arnett, S., Buzza, M. S., Shea-Donohue, T., Désilets, A., Leduc, R., Fasano, A., Bugge, T. H. and Antalis, T. M. (2012), Matriptase protects against experimental colitis and promotes intestinal barrier recovery. Inflamm Bowel Dis, 18: 1303–1314. doi: 10.1002/ibd.21930
- Issue published online: 11 JUN 2012
- Article first published online: 13 NOV 2011
- Manuscript Accepted: 28 SEP 2011
- Manuscript Received: 19 SEP 2011
- National Institutes of Health. Grant Numbers: DK48373, AI/DK49316, DK081376, CA098369, HL084387
- Maryland Stem Cell Research Fund. Grant Numbers: 0145-00, HL07698
- NIH Intramural Program
- Canadian Institutes of Health Research
- CJ Martin Training Fellowship. Grant Number: 384359
- National Health and Medical Research Council, Australia
- serine protease;
Matriptase is a membrane-anchored serine protease encoded by suppression of tumorigenicity-14 (ST14) that is required for epithelial barrier homeostasis. However, its functional role in inflammatory bowel disease (IBD) is unexplored.
Matriptase expression in control, Crohn's disease, and ulcerative colitis tissue specimens was studied by quantitative polymerase chain reaction (qPCR) and immunostaining. Matriptase function was investigated by subjecting St14 hypomorphic and control littermates to dextran sodium sulfate (DSS)-induced colitis and by siRNA silencing in cultured monolayers. Mice were analyzed for clinical, histological, molecular, and cellular effects.
Matriptase protein and ST14 mRNA levels are significantly downregulated in inflamed colonic tissues from Crohn's disease and ulcerative colitis patients. Matriptase-deficient St14 hypomorphic mice administered DSS for 7 days followed by water without DSS for 3 days develop a severe colitis, with only 30% of the St14 hypomorphic mice surviving to day 14, compared with 100% of control littermates. Persistent colitis in surviving St14 hypomorphic mice was associated with sustained cytokine production, an inability to recover barrier integrity, and enhanced claudin-2 expression. Cytokines implicated in barrier disruption during IBD suppress matriptase expression in T84 epithelial monolayers and restoration of matriptase improves barrier integrity in the cytokine-perturbed monolayers.
These data demonstrate a critical role for matriptase in restoring barrier function to injured intestinal mucosa during colitis, which is suppressed by excessive activation of the immune system. Strategies to enhance matriptase-mediated barrier recovery could be important for intervening in the cycle of inflammation associated with IBD. (Inflamm Bowel Dis 2011;)